Department of Dermatology, Venereology and Leprosy
Faculty and Staff
| Name | Designation |
|---|---|
| Prof. (Dr) Saswati Halder | Professor and Head |
| Dr. Jayanta Kumar Barua | Associate professor |
| Dr. Projna Biswas | Assistant professor |
| Dr. Nibir Biswas | RMO cum Clinical Tutor |
| Dr. Partha Pratim Sarkar | RMO cum Clinical Tutor |
| Dr. Avik Panigrahi | RMO cum Clinical Tutor |
| Dr. Prabal Samanta | Senior Resident |
| Dr. Rik Goswami | Senior Resident |
| Dr. Sabina Liangom Joana Rongong | Senior Resident |
| Dr. Padi Ampi | Senior Resident |
Academic Course
Patient Care Services
OPD attendance (2022)
| Total | 2,32, 564 |
|---|---|
| New patients | 1,96,558 |
| Old patients | 36,006 |
| Total leprosy case attended | 1635 |
| New Leprosy cases | 195 |
Total Indoor Admission (2022): 86
Minor Operative Procedures (2022)
| Procedure | Number |
|---|---|
| Biopsy | 248 |
| Electro Cautery | 116 |
| Radio Frequency | 93 |
| Chemical Frequency | 350 |
| Intra Lesional Injecton | 415 |
| Iontophoresis | 12 |
| PRP | 84 |
| Vitiligo Surgery | 5 |
| Phototherapy | 108 |
Ongoing Research Projects
| Investigator | Title of the Project |
|---|---|
| Dr. Saswati Halder (PI), Dr. Prabal Samanta (Co-PI) | A randomized open label, parallel group study to evaluate the safety to evaluate the safety and efficacy of Abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India. |
| Dr. Saswati Halder (PI), Dr. Prabal Samanta (Co-PI) | A randomized , double blind , placebo controlled , multicenter dose ranging trial to evaluate the safety of ASLAN004 in adult patient with moderate to severe atopic dermatitis. |
| Dr. Jayanta Kumar Barua (PI), Dr. Projna Biswas (Co-PI), Dr Prabal Samanta (Co-PI) | A randomized phase3, three parallel arm, assessor blind, multicentre study to evaluate the efficacy, safety and tolerability of AKPO2 cutaneous spray ( Calcipotriol+Betamethasone Dipropionate) in subjects with mild to moderate psoriasis. |
| Dr. Jayanta Barua (PI), Dr. Prabal Samanta (Co-PI) | A multicentre randomized, double blind placebo controlled Phase 3 study of Remibrutinib (Louo64) to investigate the efficacy , safety and tolerability for 52 weeks in adult chronic spontaneousurticaria patients inadequately controlled by H1-Antihistamines. |
Publications
- Barua J.K , Hajra K, Samanta P, Satsangi P, Saha T, Halder S. Clinico epidemiological study of vitiligo in a tertiary care hospital of eastern India
- Agarwal N, Hajra K, Chakraborty U, Halder S. Adverse cutaneous reactions post COVID 19 vaccination - A case series from a tertiary care centre in Eastern India.
- Hajra K, Chakraborty U, Chatterjee K, Halder S. Oral histoplasmosis presenting as a solitary ulcer on tongue in an immunocompetent adult.
- Bhanja DB, Panigrahi A, Sil A, Biswas SK. Pregnancy-onset solitary nevus lipomatosus cutaneous superficialis over the nipple: A rare cutaneous hamartoma at a peculiar site. Indian J Dermatol 2022;67:96
- Das A, Panigrahi A, Sil A, BIswas SK. Preterm neonate with violaceous skin rash. J Paediatr Child Health 2022;58(2):362-3
- Sil A, Panigrahi A. "Jellyfish in a sea of red" - a distinct dermoscopic finding in eruptive lingual papillitis. Int J Dermatol 2022:61(10):e385-7
- Sil A, Bhanja DB, Panigrahi A, Biswas SK. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian J Dermatol 2022:67(3):316
- Sil A, Panigrahi A, Chandra A, Pramanik JD. 'COVID nose' - A unique post-COVID pigmentary sequelae reminiscing Chik sign: A descriptive case series. J EurAcadDermatolVenereol. 2022;36(6):e419-21.
- Sil A, Panigrahi A. Thumb blister. J Paediatr Child Health. 2022 Dec 5. doi: 10.1111/jpc.14731. Epub ahead of print.